Sellas rises on Phase IIb TNBC data

Sellas Life Sciences Group Inc. (NASDAQ:SLS) gained $5.20 (151%) to $8.65 on Monday after reporting interim Phase IIb data showing that NeuVax nelipepimut-S plus Herceptin trastuzumab given in the adjuvant

Read the full 304 word article

User Sign In